nach oben

Erschienen in:

10.12.2019 | Original Article

Opportunistic body composition evaluation in patients with esophageal adenocarcinoma: association of survival with ¹⁸F-FDG PET/CT muscle metrics

verfasst von: Cathy Zhou, Brent Foster, Rosalie Hagge, Cameron Foster, Leon Lenchik, Abhijit J. Chaudhari, Robert D. Boutin

Erschienen in: Annals of Nuclear Medicine | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Abstract

Objective

¹⁸F-FDG PET is widely used to accurately stage numerous types of cancers. Although ¹⁸F-FDG PET/CT features of tumors aid in predicting patient prognosis, there is increasing interest in mining additional quantitative body composition data that could improve the prognostic power of ¹⁸F-FDG PET/CT, without additional examination costs or radiation exposure. The aim of this study was to determine the association between overall survival and body composition metrics derived from routine clinical ¹⁸F-FDG PET/CT examinations.

Methods

Patients who received baseline ¹⁸F-FDG PET/CT imaging during workup for newly diagnosed esophageal adenocarcinoma (EAC) were included. From these studies, psoas cross-sectional area (CSA), muscle attenuation (MA), SUV_mean, and SUV_max were obtained. Correlation with overall survival was assessed using a Cox Proportional Hazards model, controlling for age, body mass index, ¹⁸F-FDG dose, glucose level, diabetes status, in-hospital status, and tumor stage.

Results

Among the 59 patients studied, psoas MA and SUV_max were found to be significant predictors of survival (HR 0.94, 95% CI 0.88–0.99, p = 0.04, and HR 0.37, 95% CI 0.14–0.97, p = 0.04, respectively) and remained independent predictors. Psoas CSA and SUV_mean did not significantly influence survival outcomes.

Conclusions

Characterization of psoas muscles as a surrogate marker for sarcopenia on baseline ¹⁸F-FDG PET/CT imaging is relatively easily obtained and may offer additional prognostic value in patients with EAC.

Hur C, Miller M, Kong CY, Dowling EC, Nattinger KJ, Dunn M, et al. Trends in esophageal adenocarcinoma incidence and mortality. Cancer. 2013;119(6):1149–58.PubMed

Lagergren J, Lagergren P. Recent developments in esophageal adenocarcinoma. CA Cancer J Clin. 2013;63(4):232–48.PubMed

Barber TW, Duong CP, Leong T, Bressel M, Drummond EG, Hicks RJ. 18F-FDG PET/CT has a high impact on patient management and provides powerful prognostic stratification in the primary staging of esophageal cancer: a prospective study with mature survival data. J Nucl Med. 2012;53(6):864–71.PubMed

Kauppi JT, Oksala N, Salo JA, Helin H, Karhumaki L, Kemppainen J, et al. Locally advanced esophageal adenocarcinoma: response to neoadjuvant chemotherapy and survival predicted by ([18F])FDG-PET/CT. Acta Oncol. 2012;51(5):636–44.PubMed

Omloo JM, van Heijl M, Hoekstra OS, van Berge Henegouwen MI, van Lanschot JJ, Sloof GW. FDG-PET parameters as prognostic factor in esophageal cancer patients: a review. Ann Surg Oncol. 2011;18(12):3338–52.PubMedPubMedCentral

Schollaert P, Crott R, Bertrand C, D’Hondt L, Borght TV, Krug B. A systematic review of the predictive value of (18)FDG-PET in esophageal and esophagogastric junction cancer after neoadjuvant chemoradiation on the survival outcome stratification. J Gastrointest Surg. 2014;18(5):894–905.PubMed

Walker AJ, Spier BJ, Perlman SB, Stangl JR, Frick TJ, Gopal DV, et al. Integrated PET/CT fusion imaging and endoscopic ultrasound in the pre-operative staging and evaluation of esophageal cancer. Mol Imaging Biol. 2011;13(1):166–71.PubMed

Hatt M, Visvikis D, Albarghach NM, Tixier F, Pradier O, Cheze-le Rest C. Prognostic value of 18F-FDG PET image-based parameters in oesophageal cancer and impact of tumour delineation methodology. Eur J Nucl Med Mol Imaging. 2011;38(7):1191–202.PubMed

Hyun SH, Choi JY, Shim YM, Kim K, Lee SJ, Cho YS, et al. Prognostic value of metabolic tumor volume measured by 18F-fluorodeoxyglucose positron emission tomography in patients with esophageal carcinoma. Ann Surg Oncol. 2010;17(1):115–22.PubMed

10.

Tamandl D, Gore RM, Fueger B, Kinsperger P, Hejna M, Paireder M, et al. Change in volume parameters induced by neoadjuvant chemotherapy provide accurate prediction of overall survival after resection in patients with oesophageal cancer. Eur Radiol. 2016;26(2):311–21.PubMed

11.

Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al. Sarcopenia: European consensus on definition and diagnosis: report of the european working group on sarcopenia in older people. Age Ageing. 2010;39(4):412–23.PubMedPubMedCentral

12.

Boutin RD, Yao L, Canter RJ, Lenchik L. Sarcopenia: current concepts and imaging implications. AJR Am J Roentgenol. 2015;205(3):W255–66.PubMed

13.

Tan BH, Brammer K, Randhawa N, Welch NT, Parsons SL, James EJ, et al. Sarcopenia is associated with toxicity in patients undergoing neo-adjuvant chemotherapy for oesophago-gastric cancer. Eur J Surg Oncol. 2015;41(3):333–8.PubMed

14.

Evans WJ. Skeletal muscle loss: cachexia, sarcopenia, and inactivity. Am J Clin Nutr. 2010;91(4):1123S–7S.PubMed

15.

Mourtzakis M, Prado CM, Lieffers JR, Reiman T, McCargar LJ, Baracos VE. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab. 2008;33(5):997–1006.PubMed

16.

Yip C, Goh V, Davies A, Gossage J, Mitchell-Hay R, Hynes O, et al. Assessment of sarcopenia and changes in body composition after neoadjuvant chemotherapy and associations with clinical outcomes in oesophageal cancer. Eur Radiol. 2014;24(5):998–1005.PubMed

17.

Park SY, Yoon JK, Lee SJ, Haam S, Jung J. Prognostic value of preoperative total psoas muscle area on long-term outcome in surgically treated oesophageal cancer patients. Interact CardioVasc Thorac Surg. 2017;24(1):13–9.PubMed

18.

Paireder M, Asari R, Kristo I, Rieder E, Tamandl D, Ba-Ssalamah A, et al. Impact of sarcopenia on outcome in patients with esophageal resection following neoadjuvant chemotherapy for esophageal cancer. Eur J Surg Oncol. 2017;43(2):478–84.PubMed

19.

Tamandl D, Paireder M, Asari R, Baltzer PA, Schoppmann SF, Ba-Ssalamah A. Markers of sarcopenia quantified by computed tomography predict adverse long-term outcome in patients with resected oesophageal or gastro-oesophageal junction cancer. Eur Radiol. 2016;26(5):1359–67.PubMed

20.

Sabel MS, Terjimanian M, Conlon AS, Griffith KA, Morris AM, Mulholland MW, et al. Analytic morphometric assessment of patients undergoing colectomy for colon cancer. J Surg Oncol. 2013;108(3):169–75.PubMed

21.

Grotenhuis BA, Shapiro J, van Adrichem S, de Vries M, Koek M, Wijnhoven BP, et al. Sarcopenia/muscle mass is not a prognostic factor for short- and long-term outcome after esophagectomy for cancer. World J Surg. 2016;40(11):2698–704.PubMedPubMedCentral

22.

Reisinger KW, Bosmans JW, Uittenbogaart M, Alsoumali A, Poeze M, Sosef MN, et al. Loss of skeletal muscle mass during neoadjuvant chemoradiotherapy predicts postoperative mortality in esophageal cancer surgery. Ann Surg Oncol. 2015;22(13):4445–52.PubMedPubMedCentral

23.

Englesbe MJ, Patel SP, He K, Lynch RJ, Schaubel DE, Harbaugh C, et al. Sarcopenia and mortality after liver transplantation. J Am Coll Surg. 2010;211(2):271–8.PubMedPubMedCentral

24.

Hasselager R, Gogenur I. Core muscle size assessed by perioperative abdominal CT scan is related to mortality, postoperative complications, and hospitalization after major abdominal surgery: a systematic review. Langenbecks Arch Surg. 2014;399(3):287–95.PubMed

25.

Lee JS, He K, Harbaugh CM, Schaubel DE, Sonnenday CJ, Wang SC, et al. Frailty, core muscle size, and mortality in patients undergoing open abdominal aortic aneurysm repair. J Vasc Surg. 2011;53(4):912–7.PubMed

26.

Sheetz KH, Zhao L, Holcombe SA, Wang SC, Reddy RM, Lin J, et al. Decreased core muscle size is associated with worse patient survival following esophagectomy for cancer. Dis Esophagus. 2013;26(7):716–22.PubMedPubMedCentral

27.

Englesbe MJ, Lee JS, He K, Fan L, Schaubel DE, Sheetz KH, et al. Analytic morphomics, core muscle size, and surgical outcomes. Ann Surg. 2012;256(2):255–61.PubMed

28.

Jones KI, Doleman B, Scott S, Lund JN, Williams JP. Simple psoas cross-sectional area measurement is a quick and easy method to assess sarcopenia and predicts major surgical complications. Colorectal Dis. 2015;17(1):O20–6.PubMed

29.

Xi M, Liao Z, Hofstetter WL, Komaki R, Ho L, Lin SH. (18)F-FDG PET response after induction chemotherapy can predict who will benefit from subsequent esophagectomy after chemoradiotherapy for esophageal adenocarcinoma. J Nucl Med. 2017;58(11):1756–63.PubMedPubMedCentral

30.

Miller BS, Ignatoski KM, Daignault S, Lindland C, Doherty M, Gauger PG, et al. Worsening central sarcopenia and increasing intra-abdominal fat correlate with decreased survival in patients with adrenocortical carcinoma. World J Surg. 2012;36(7):1509–16.PubMed

31.

Sabel MS, Lee J, Cai S, Englesbe MJ, Holcombe S, Wang S. Sarcopenia as a prognostic factor among patients with stage III melanoma. Ann Surg Oncol. 2011;18(13):3579–85.PubMed

32.

Veld J, Vossen JA, De Amorim Bernstein K, Halpern EF, Torriani M, Bredella MA. Adipose tissue and muscle attenuation as novel biomarkers predicting mortality in patients with extremity sarcomas. Eur Radiol. 2016;26(12):4649–55.PubMed

33.

Foster B, Gedeon D, Nittur V, Boutin RD, Badawi R, Canter R, et al. Skeletal muscle quantity and quality: feasibility of mining novel metrics from routine clinical 18F-FDG-PET/CT. J Nucl Med. 2015;56(supplement 3):1773.

34.

Lee SM, Jun DW, Cho YK, Jang EC, Kwak JH. Association between Psoas muscle fdg uptake and metabolic syndrome by 18f-fluorodeoxyglucose positron emission tomography: may psoas muscle Fdg uptake use as a biomarker for impaired metabolic health? Hepatology. 2015;62:1236A.

35.

Lo J, Bernstein LE, Canavan B, Torriani M, Jackson MB, Ahima RS, et al. Effects of TNF-alpha neutralization on adipocytokines and skeletal muscle adiposity in the metabolic syndrome. Am J Physiol Endocrinol Metab. 2007;293(1):E102–9.PubMedPubMedCentral

36.

Zoico E, Corzato F, Bambace C, Rossi AP, Micciolo R, Cinti S, et al. Myosteatosis and myofibrosis: relationship with aging, inflammation and insulin resistance. Arch Gerontol Geriatr. 2013;57(3):411–6.PubMedPubMedCentral

37.

Tateyama M, Fujihara K, Misu T, Arai A, Kaneta T, Aoki M. Clinical values of FDG PET in polymyositis and dermatomyositis syndromes: imaging of skeletal muscle inflammation. BMJ Open. 2015;5(1):e006763.PubMedPubMedCentral

38.

Tanaka S, Ikeda K, Uchiyama K, Iwamoto T, Sanayama Y, Okubo A, et al. [18F]FDG uptake in proximal muscles assessed by PET/CT reflects both global and local muscular inflammation and provides useful information in the management of patients with polymyositis/dermatomyositis. Rheumatol (Oxford). 2013;52(7):1271–8.

39.

Narici MV, Maffulli N. Sarcopenia: characteristics, mechanisms and functional significance. Br Med Bull. 2010;95:139–59.PubMed

40.

Goodpaster BH, Kelley DE, Thaete FL, He J, Ross R. Skeletal muscle attenuation determined by computed tomography is associated with skeletal muscle lipid content. J Appl Physiol. 2000;89(1):104–10.PubMed

41.

Goodpaster BH, Thaete FL, Kelley DE. Composition of skeletal muscle evaluated with computed tomography. Ann N Y Acad Sci. 2000;904:18–24.PubMed

42.

Taaffe DR, Henwood TR, Nalls MA, Walker DG, Lang TF, Harris TB. Alterations in muscle attenuation following detraining and retraining in resistance-trained older adults. Gerontology. 2009;55(2):217–23.PubMed

43.

Davies NJ, Batehup L, Thomas R. The role of diet and physical activity in breast, colorectal, and prostate cancer survivorship: a review of the literature. Br J Cancer. 2011;105(Suppl 1):S52–73.PubMedPubMedCentral

44.

Faber J, Uitdehaag MJ, Spaander M, van Steenbergen-Langeveld S, Vos P, Berkhout M, et al. Improved body weight and performance status and reduced serum PGE2 levels after nutritional intervention with a specific medical food in newly diagnosed patients with esophageal cancer or adenocarcinoma of the gastro-esophageal junction. J Cachexia Sarcopenia Muscle. 2015;6(1):32–44.PubMedPubMedCentral

45.

Ryan AM, Reynolds JV, Healy L, Byrne M, Moore J, Brannelly N, et al. Enteral nutrition enriched with eicosapentaenoic acid (EPA) preserves lean body mass following esophageal cancer surgery: results of a double-blinded randomized controlled trial. Ann Surg. 2009;249(3):355–63.PubMed

46.

Nakashima Y, Saeki H, Nakanishi R, Sugiyama M, Kurashige J, Oki E, et al. Assessment of sarcopenia as a predictor of poor outcomes after esophagectomy in elderly patients with esophageal cancer. Ann Surg. 2018;267(6):1100–4.PubMed

47.

Elliott JA, Doyle SL, Murphy CF, King S, Guinan EM, Beddy P, et al. Sarcopenia: prevalence, and impact on operative and oncologic outcomes in the multimodal management of locally advanced esophageal cancer. Ann Surg. 2017;266(5):822–30.PubMed

48.

Panje CM, Hong L, Hayoz S, Baracos VE, Herrmann E, Garcia Schuler H, et al. Skeletal muscle mass correlates with increased toxicity during neoadjuvant radiochemotherapy in locally advanced esophageal cancer: a SAKK 75/08 substudy. Radiat Oncol. 2019;14(1):166.PubMedPubMedCentral

49.

Murimwa GZ, Venkat PS, Jin W, Leuthold S, Latifi K, Almhanna K, et al. Impact of sarcopenia on outcomes of locally advanced esophageal cancer patients treated with neoadjuvant chemoradiation followed by surgery. J Gastrointest Oncol. 2017;8(5):808–15.PubMedPubMedCentral

50.

Siegel BA. Cassen lecture-what have we learned from the national oncologic PET registry? J Nucl Med. 2014;55(12):9N–15N.PubMed

51.

Bettinardi V, Danna M, Savi A, Lecchi M, Castiglioni I, Gilardi MC, et al. Performance evaluation of the new whole-body PET/CT scanner: discovery ST. Eur J Nucl Med Mol Imaging. 2004;31(6):867–81.PubMed

52.

Bettinardi V, Presotto L, Rapisarda E, Picchio M, Gianolli L, Gilardi MC. Physical performance of the new hybrid PETCT Discovery-690. Med Phys. 2011;38(10):5394–411.PubMed

Titel: Opportunistic body composition evaluation in patients with esophageal adenocarcinoma: association of survival with 18F-FDG PET/CT muscle metrics
verfasst von: Cathy Zhou
Brent Foster
Rosalie Hagge
Cameron Foster
Leon Lenchik
Abhijit J. Chaudhari
Robert D. Boutin
Publikationsdatum: 10.12.2019
Verlag: Springer Singapore
Erschienen in: Annals of Nuclear Medicine / Ausgabe 3/2020
Print ISSN: 0914-7187
Elektronische ISSN: 1864-6433
DOI: https://doi.org/10.1007/s12149-019-01429-7

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Opportunistic body composition evaluation in patients with esophageal adenocarcinoma: association of survival with ¹⁸F-FDG PET/CT muscle metrics

Abstract

Objective

Methods

Results

Conclusions

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Objective

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2020

Evaluation of the total distribution volume of 18F-FBPA in normal tissues of healthy volunteers by non-compartmental kinetic modeling

Predominance and homogeneity patterns of physiological FDG accumulation in thoracic and lumbar vertebrae: suspected mechanism of “bone pseudometastasis” on FDG-PET in Japanese patients with esophageal cancer

Relationship between decreased cerebral blood flow and amnesia after microsurgery for anterior communicating artery aneurysm

Reply to Zaragori et al.: “Is IDH mutation status associated with 18F-FDopa PET uptake”

Ordered subset expectation maximisation vs Bayesian penalised likelihood reconstruction algorithm in 18F-PSMA-1007 PET/CT

Is IDH mutation status associated with 18F-FDopa PET uptake?